Reset filter
Nyckelord
Concomitant Medication ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

467 Sökresultat.
Relevans Bedömning Nya först Gamla först

Concomitant Medications Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238

- 22.05.17 - 1 Formulär, 2 Item-grupper, 10 Dataelement, 1 Språk
Item-grupper: Concomitant Medications, Medication
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1

Concomitant Medications Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

- 20.05.17 - 1 Formulär, 2 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: Concomitant Medication, Medication
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1

Genetic Screening For HLA-B*5701 in Patients with HIV Concomitant Medications NCT00340080 - Genetic Screening For HLA-B*5701 Concomitant Medications NCT00340080

- 25.04.17 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Concomitant Medications, Concomitant Antiretroviral Therapy
NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Concomitant Medications Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Penultimate Visit Concomitant Medication ACE Inhibitors and Statines PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 23.03.17 - 1 Formulär, 3 Item-grupper, 6 Dataelement, 1 Språk
Item-grupper: Concomitant Medication, ACE Inhibitors, Restricted Concomitant Medication
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Penultimate Visit (Next to last Visit) Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

End of Trial Concomitant Medication ACE Inhibitors PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 21.02.17 - 1 Formulär, 3 Item-grupper, 6 Dataelement, 1 Språk
Item-grupper: Concomitant Medication, ACE Inhibitors, Restricted Concomitant Medication
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. End of Trial Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

Concomitant Medication Visit 5 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 21.02.17 - 1 Formulär, 3 Item-grupper, 6 Dataelement, 1 Språk
Item-grupper: Concomitant Medication, ACE Inhibitors, Restricted Concomitant Medication
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Visit 5 (Month 12) Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

Visit 1 Month 0 Toast Criteria Concomitant Medication ACE Inhibitors PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 20.02.17 - 1 Formulär, 3 Item-grupper, 5 Dataelement, 1 Språk
Item-grupper: Toast Criteria, Concomitant Medication, ACE Inhibitors
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Visit 1 (Month 0) Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

Treatment Visit 2 Month 1 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 15.02.17 - 1 Formulär, 4 Item-grupper, 8 Dataelement, 1 Språk
Item-grupper: Concomitant Medication, ACE Inhibitors, Restricted Concomitant Medication, Tobacco Use Status
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300

- 14.02.17 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Concomitant Non-Drug Therapy
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.

Throughout: Concomitant Medication 2A [CM_2A] NCT01117584

- 04.02.17 - 1 Formulär, 1 Item-grupp, 21 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Concomitant Medication CRFs Multiple Sclerosis Tysabri NCT00027300

- 30.01.17 - 1 Formulär, 1 Item-grupp, 70 Dataelement, 1 Språk
Item-grupp: Concomitant Medication
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.

University Hospital Essen Medication

- 24.01.17 - 1 Formulär, 1 Item-grupp, 14 Dataelement, 1 Språk
Item-grupp: Default Itemgroup
Hospital routine documentation models at the University Hospital Essen. Tables were derived from the Medico Information System. Original table name: x2433med

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial